American Journal of Cardiology
Volume 103, Issue 4 , Pages 476-481 , 15 February 2009

Usefulness of Serum Cathepsin L as an Independent Biomarker in Patients With Coronary Heart Disease

  • Yingxian Liu, MD

      Affiliations

    • Department of Medicine, Peking Union Medical College Hospital, Beijing, China
    • Department of Cardiology, Second Xiangya Hospital, Central South University, Hunan, China
    • ,
  • Xiangping Li, MD, PhD

      Affiliations

    • Department of Cardiology, Second Xiangya Hospital, Central South University, Hunan, China
    • Corresponding Author InformationCorresponding author: Tel: 617-525-4358; or 86-139-7-487-9019 (X. Li); fax: 617-525-4380
    • ,
  • Daoquan Peng, MD, PhD

      Affiliations

    • Department of Cardiology, Second Xiangya Hospital, Central South University, Hunan, China
    • ,
  • Zheng Tan, MD

      Affiliations

    • Department of Cardiology, Second Xiangya Hospital, Central South University, Hunan, China
    • ,
  • Hongmin Liu, MD

      Affiliations

    • Department of Cardiology, Second Xiangya Hospital, Central South University, Hunan, China
    • ,
  • Yingnan Qing, MD

      Affiliations

    • Department of Cardiology, Second Xiangya Hospital, Central South University, Hunan, China
    • ,
  • Yanqiong Xue, MD

      Affiliations

    • Department of Cardiology, Second Xiangya Hospital, Central South University, Hunan, China
    • ,
  • Guo-Ping Shi, DSc

      Affiliations

    • Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 617-525-4358; or 86-139-7-487-9019 (X. Li); fax: 617-525-4380

Received 21 August 2008 ,Revised 2 October 2008 ,Accepted 2 October 2008.

References 

  1. Liu J, Sukhova GK, Yang JT, Sun J, Ma L, Ren A, et al. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis. 2006;184:302–311
  2. Li W, Yuan XM. Increased expression and translocation of lysosomal cathepsins contribute to macrophage apoptosis in atherogenesis. Ann N Y Acad Sci. 2004;1030:427–433
  3. Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR, et al Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med. 2005;11:206–213
  4. Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science. 1998;280:394–395
  5. Kitamoto S, Sukhova GK, Sun J, Yang M, Libby P, Love V, et al. Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice. Circulation. 2007;115:2065–2075
  6. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest. 1998;102:576–583
  7. Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol. 1997;59:63–88
  8. Villadangos JA, Bryant RA, Deussing J, Driessen C, Lennon-Duménil AM, Riese RJ, et al. Proteases involved in MHC class II antigen presentation. Immunol Rev. 1999;172:109–120
  9. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004;5:443–453
  10. Vonend O, Apel T, Amann K, Sellin L, Stegbauer J, Ritz E, et al. Modulation of gene expression by moxonidine in rats with chronic renal failure. Nephrol Dial Transplant. 2004;19:2217–2222
  11. Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-alpha–induced apoptosis in liver injury. J Cell Mol Med. 2004;8:445–454
  12. Sriveny D, Raina OK, Yadav SC, Chandra D, Jayraw AK, Singh M, et al. Cathepsin L cysteine proteinase in the diagnosis of bovine Fasciola gigantica infection. Vet Parasitol. 2006;135:25–31
  13. Everts V, Korper W, Hoeben KA, Jansen ID, Bromme D, Cleutjens KB, et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. Bone Miner Res. 2006;21:1399–1408
  14. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969
  15. Braunward E. Unstable angina: a classification. Circulation. 1989;80:410–414
  16. Judkins MP. Percutaneous transfemoral selective coronary arteriography. Radiol Clin North Am. 1968;6:467–492
  17. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606
  18. Auer J, Berent R, Lassnig E, Eber B. C-reactive protein and coronary artery disease. Jpn Heart J. 2002;43:607–619
  19. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:1359–1366
  20. Adams MR, Nakagomi A, Keech A, Robinson J, McCredie R, Bailey BP, et al. Carotid intima–media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation. 1995;92:2127–2134
  21. Platt MO, Ankeny RF, Jo H. Laminar shear stress inhibits cathepsin L activity in endothelial cells. Arterioscler Thromb Vasc Biol. 2006;26:1784–1790
  22. Cheng XW, Murohara T, Kuzuya M, Izawa H, Sasaki T, Obata K, et al Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol. 2008;173:358–369
  23. Norja S, Nuutila L, Karhunen PJ, Goebeler S. C-reactive protein in vulnerable coronary plaques. J Clin Pathol. 2007;60:545–548
  24. Geluk CA, Post WJ, Hillege HL, Tio RA, Tijssen JG, van Dijk RB, et al. C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: data from the prospective PREVEND cohort. Atherosclerosis. 2008;196:372–382
  25. Liu J, Ma L, Yang J, Ren A, Sun Z, Yan G, et al. Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis. 2006;186:411–419
  26. Petermann I, Mayer C, Stypmann J, Biniossek ML, Tobin DJ, Engelen MA, et al. Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice. FASEB J. 2006;20:1266–1268
  27. Stypmann J, Gläser K, Roth W, Tobin DJ, Petermann I, Matthias R, et al. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci U S A. 2002;99:6234–6239

 This study was supported in part by Grant 03SSY3080 from the Department of Science and Technology of Hunan, Hunan, China (to Dr. Li); Grant 0840118N from the American Heart Association, Dallas, Texas (to Dr. Shi); and Grants HL60942, HL67283, and HL81090 from the National Institutes of Health, Bethesda, Maryland (to Dr. Shi).

PII: S0002-9149(08)01887-0

doi: 10.1016/j.amjcard.2008.10.011

American Journal of Cardiology
Volume 103, Issue 4 , Pages 476-481 , 15 February 2009

Article Tools

* Image Usage & Resolution